Alkermes (ALKS) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
6 Apr, 2026Executive summary
Annual general meeting scheduled for May 20, 2026, at the company's Dublin offices.
Shareholders as of March 13, 2026, are eligible to vote on key proposals.
Proxy materials, including the notice and annual report, are available online and by request.
Voting matters and shareholder proposals
Election of nine directors for a one-year term until the 2027 annual meeting.
Advisory vote on executive compensation (say-on-pay).
Ratification of PricewaterhouseCoopers LLP as independent auditor and authorization for the Audit and Risk Committee to set remuneration.
Approval of amendments to the 2018 Stock Option and Incentive Plan.
Renewal of Board authority to allot and issue shares and to disapply statutory pre-emption rights under Irish law.
Board of directors and corporate governance
Board recommends voting for all director nominees and all proposals.
Shareholders may appoint proxies, including individuals not specified on the proxy card.
Latest events from Alkermes
- ALKS-2680 improves wakefulness and sleep latency with strong safety and CNS expansion plans.ALKS
Status Update21 Jul 2026 - Orexin pipeline drives growth, with strong commercial execution and expanding clinical opportunities.ALKS
Jefferies London Healthcare Conference 20249 Jul 2026 - Phase II results for alixorexton in NT1 showed strong efficacy and safety, with Phase III plans underway.ALKS
AGM 20259 Jul 2026 - Proprietary product sales rose 16% year-over-year, driving robust Q2 profitability despite lower royalties.ALKS
Q2 20248 Jul 2026 - Orexin agonist pipeline shows strong efficacy and safety, positioning for broad market impact.ALKS
Goldman Sachs 46th Annual Global Healthcare Conference8 Jul 2026 - Alixorexton showed significant efficacy and safety in NT2, supporting phase III advancement.ALKS
Study Update8 Jul 2026 - 2025 saw strong revenue and profitability; 2026 guidance reflects Avadel integration and growth.ALKS
Q4 202529 Jun 2026 - Alixorexton improved wakefulness, sleepiness, fatigue, and cognition in NT2 with good tolerability.ALKS
Sleep 2026 conference presentation25 Jun 2026 - Orexin agonist advances, Avadel integration, and CEO transition mark a pivotal year.ALKS
Goldman Sachs 47th Annual Global Healthcare Conference 202611 Jun 2026 - Shareholders are invited to vote on key proposals at the May 20, 2026, annual meeting.ALKS
Proxy filing13 May 2026